LitCovid-sample-Enju  

PMC:7205724 / 122-484 JSONTXT 14 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T18 8-9 -COMMA- denotes ,
T19 10-25 NNS denotes immunoglobulins
T20 25-26 -COMMA- denotes ,
T21 27-30 CC denotes and
T22 31-46 NNS denotes corticosteroids
T23 48-58 NNS denotes Highlights
T24 59-60 IN denotes •
T25 62-66 NNP denotes IVIG
T26 66-67 -COMMA- denotes ,
T27 68-76 VBN denotes combined
T28 77-81 IN denotes with
T29 82-95 NN denotes moderate-dose
T30 96-98 IN denotes of
T31 99-114 NNS denotes corticosteroids
T32 114-115 -COMMA- denotes ,
T33 116-121 MD denotes might
T34 122-129 VB denotes improve
T35 130-137 NN denotes patient
T36 138-146 NNS denotes outcomes
T37 148-149 PDT denotes •
T38 151-154 DT denotes The
T39 155-158 NN denotes use
T40 159-161 IN denotes of
T41 162-177 NNS denotes corticosteroids
T42 178-183 MD denotes might
T43 184-194 VB denotes accelerate
T44 195-203 NN denotes recovery
T45 204-208 IN denotes from
T46 209-217 NN denotes COVID-19
T47 219-220 PDT denotes •
T48 222-224 DT denotes No
T49 225-235 VBN denotes controlled
T50 236-244 JJ denotes clinical
T51 245-251 NNS denotes trials
T52 252-257 VBP denotes exist
T53 258-260 IN denotes on
T54 261-264 DT denotes the
T55 265-268 NN denotes use
T56 269-271 IN denotes of
T57 272-287 NNS denotes corticosteroids
T58 288-291 IN denotes for
T59 292-300 NN denotes COVID-19
T60 302-303 LS denotes •
T61 305-308 NN denotes IL6
T62 309-319 VBZ denotes correlates
T63 320-324 IN denotes with
T64 325-333 NN denotes severity
T65 333-334 -COMMA- denotes ,
T66 335-346 NN denotes criticality
T67 346-347 -COMMA- denotes ,
T68 348-353 JJ denotes viral
T69 354-358 NN denotes load
T70 358-359 -COMMA- denotes ,
R16 T19 T18 arg2Of immunoglobulins,","
R17 T21 T20 arg1Of and,","
R18 T18 T21 arg1Of ",",and
R19 T22 T21 arg2Of corticosteroids,and
R20 T25 T24 arg1Of IVIG,•
R21 T25 T26 arg1Of IVIG,","
R22 T25 T27 arg2Of IVIG,combined
R23 T27 T28 arg1Of combined,with
R24 T29 T28 arg2Of moderate-dose,with
R25 T29 T30 arg1Of moderate-dose,of
R26 T31 T30 arg2Of corticosteroids,of
R27 T34 T32 arg1Of improve,","
R28 T25 T33 arg1Of IVIG,might
R29 T34 T33 arg2Of improve,might
R30 T25 T34 arg1Of IVIG,improve
R31 T36 T34 arg2Of outcomes,improve
R32 T36 T35 arg1Of outcomes,patient
R33 T39 T37 arg1Of use,•
R34 T39 T38 arg1Of use,The
R35 T39 T40 arg1Of use,of
R36 T41 T40 arg2Of corticosteroids,of
R37 T39 T42 arg1Of use,might
R38 T43 T42 arg2Of accelerate,might
R39 T39 T43 arg1Of use,accelerate
R40 T44 T43 arg2Of recovery,accelerate
R41 T44 T45 arg1Of recovery,from
R42 T46 T45 arg2Of COVID-19,from
R43 T51 T47 arg1Of trials,•
R44 T51 T48 arg1Of trials,No
R45 T51 T49 arg2Of trials,controlled
R46 T51 T50 arg1Of trials,clinical
R47 T51 T52 arg1Of trials,exist
R48 T52 T53 arg1Of exist,on
R49 T55 T53 arg2Of use,on
R50 T55 T54 arg1Of use,the
R51 T55 T56 arg1Of use,of
R52 T57 T56 arg2Of corticosteroids,of
R53 T55 T58 arg1Of use,for
R54 T59 T58 arg2Of COVID-19,for
R55 T62 T60 arg1Of correlates,•
R56 T61 T62 arg1Of IL6,correlates
R57 T62 T63 arg1Of correlates,with
R59 T64 T65 arg1Of severity,","
R60 T66 T65 arg2Of criticality,","
R61 T65 T67 arg1Of ",",","
R62 T69 T67 arg2Of load,","
R63 T69 T68 arg1Of load,viral